By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



5 Science Park
395 Winchester Avenue
New Haven  Connecticut  06511  U.S.A.
Phone: 203-535-1456 Fax: n/a


Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. This strategy of degradation versus protein inhibition holds several advantages including the potential to target proteins that are not currently ‘druggable’ using a small molecule approach.

Key Statistics

Ownership: Private

Web Site: Arvinas
Employees: n/a


Company News
Arvinas Secures $41.6 Million Series B Financing - Appoints New Board Members 10/21/2015 10:00:42 AM
Arvinas Inks $300 Million Deal With Genentech (RHHBY) Over Protein Degradation Technology 10/1/2015 6:30:24 AM
Arvinas Appoints Robert Kleinfield As Chief Development Officer 9/23/2015 11:33:09 AM
Arvinas Publishes First Peer-Reviewed Paper On Its Proprietary PROTAC Technology 6/5/2015 6:51:42 AM
Arvinas Strikes $434 Million Collaboration with Merck & Co. (MRK) to Continue Thriving in Connecticut 4/7/2015 5:44:41 AM
Arvinas Appoints Manuel Litchman As President And Chief Executive Officer 1/12/2015 9:09:21 AM
Arvinas Hires Jim Winkler As Chief Scientific Officer 2/11/2014 10:18:34 AM
Yale University Spinout Arvinas Lands $18.25 Million to Advance Clinical Programs Focused on Protein Degradation 9/27/2013 7:57:13 AM